EMERYVILLE, Calif.--(BUSINESS WIRE)--April 10, 2006--BioTime, Inc. (OTCBB:BTIM - News) announced today that it has entered into a license agreement with Summit Pharmaceuticals International Corporation ("Summit") to develop Hextend® and PentaLyte® in the People's Republic of China and Taiwan. Summit has sublicensed to a pharmaceutical company the right to use our patents, trademarks and other proprietary information to manufacture and market Hextend® and PentaLyte® in those countries. Summit or its sublicensee must obtain regulatory approval before Hextend® and PentaLyte® can be brought to the market in China and Taiwan.
